Journal Information
Vol. 47. Issue S7.
Hipertensión pulmonar
Pages 2-6 (November 2011)
Share
Share
Download PDF
More article options
Vol. 47. Issue S7.
Hipertensión pulmonar
Pages 2-6 (November 2011)
Full text access
Evaluación diagnóstica y pronóstica del paciente con hipertensión pulmonar
Diagnostic and prognostic evaluation in patients with pulmonary hypertension
Visits
17493
Francisco Javier Mazo Etxaniza, Luis Alberto Ruiz Iturriagab,
Corresponding author
LUISALBERTO.RUIZITURRIAGA@OSAKIDETZA.NET

Autor para correspondencia.
a Servicio de Neumología, Hospital de Basurto, Bizkaia, España
b Servicio de Neumología, Hospital de Cruces, Bizkaia, España
This item has received
Article information
Resumen

La hipertensión pulmonar (HP) es un trastorno hemodinámico que se puede observar en el contexto de una serie de patologías de diferente índole. Se define por la presencia de un valor medio de presión en arteria pulmonar (PAPm) ≥25mmHg. Desde un punto de vista clínico, se clasifica en 5 grupos; de ellos el grupo I o hipertensión arterial pulmonar, aunque infrecuente, merece especial consideración por las implicaciones terapéuticas específicas que conlleva. Sobre la base de una sospecha clínica y/o resultado de un ecocardiograma, el diagnóstico de esta entidad se basa en el seguimiento de un estricto protocolo que debe incluir la realización de un cateterismo cardiaco derecho. La HP es una enfermedad progresiva y grave cuyo pronóstico va a depender fundamentalmente del grado de afectación del ventrículo derecho. Una vez confirmado el diagnóstico, resulta indispensable evaluar la gravedad del cuadro para instaurar el tratamiento más acorde a la situación clínica del paciente. Para ello, utilizaremos diversos parámetros clínicos, biológicos, ecocardiográficos-hemodinámicos y relacionados con la capacidad de esfuerzo.

Palabras clave:
Hipertensión pulmonar
Algoritmo diagnóstico
Ecocardiografía
Cateterismo cardiaco derecho
Pronóstico
Abstract

Pulmonary hypertension (PH) is a hemodynamic disorder that occurs in a series of distinct diseases and is defined by the presence of a mean pulmonary artery pressure of ≥25mm Hg. Clinically, this disorder is classified in five groups. Of these, group I, or pulmonary arterial hypertension (PAH), although infrequent, deserves special attention due to the specific therapeutic implications involved. Based on clinical suspicion and/or the results of echocardiogram, the diagnosis of this entity is established by following a strict protocol that should include right-sided cardiac catheterization. PH is a severe, progressive disease whose prognosis mainly depends on the degree of right ventricular involvement. Once the diagnosis has been confirmed, severity must be evaluated to initiate the most appropriate treatment for the patient's status. To do this, several clinical, biological, and echocardiographic-hemodynamic parameters and indicators of exercise capacity can be used.

Keywords:
Pulmonary hypertension
Diagnostic algorithm
Echocardiography
Right-sided cardiac catheterization
Prognosis
Full text is only aviable in PDF
Bibliografía
[1.]
N. Galié, M. Palazzini, A. Manes.
Pulmonary hypertension pulmonary arterial hypertension: a clarification is needed.
Eur Respir J., 36 (2010), pp. 986-990
[2.]
G. Simmonneau, I. Ribbins, M. Beghetti, R. Channick, M. Delcroix, C. Denton, et al.
Updated clinical classification of pulmonary hypertension.
J Am Coll Cardiol., 54 (2009), pp. s43-s54
[3.]
N. Galiè, M. Hoeper, M. Humbert, A. Torbicki, J.I. Vachiery, J.A. Barberá, et al.
Guidelines for the diagnosis treatment of pulmonary hypertension.
Eur Heart J., 30 (2009), pp. 2493-2537
[4.]
P. Escribano, J.A. Barberá, V. Suberviola.
Evaluación diagnostica y pronostica actual de la HP.
Rev Esp Cardiol., 63 (2010), pp. 583-596
[5.]
M. Hoeper, J. Barberá, R. Channick, P. Hassoun, I. Lang, A. Manes, et al.
Diagnosis assesement and treatment of non arterial pulmonary hypertension.
J Am Coll Cardiol., 54 (2009), pp. s85-s96
[6.]
V. Cottin, H. Nunes, P. Brillet, P. Delaval, G. Devouassoux, I. Tillie-Leblond, et al.
Combined pulmonary fibrosis emphysema a distinct underrecognised entity.
Eur Respir J., 26 (2005), pp. 586-593
[7.]
E. Gabbay, W. Yeow, D. Playford.
Pulmonary arterial hipertension is an uncommon cause of pulmonary hypertension in an unselected population: the Armadale echocardiography study.
Am J Respir Crit Care Med., 175 (2007), pp. A713
[8.]
V. Pengo, A. Lensing, M. Prins, A. Marchori, B. Davidson, F. Tiozzo, et al.
Incidence of chronic thromboembolic pulmonary hipertensión after pulmonary embolism.
N Engl J Med., 350 (2004), pp. 2257-2264
[9.]
P.G. Yock, R.L. Popp.
Noninvasive estimation of right ventricular systolic pressure by dopppler ultrasound in patientes with tricúspide regurgitation.
Circulation., 70 (1984), pp. 657-662
[10.]
S.F. Nagueh, S.F. Nagueh, C.P. Appleton, T.C. Gillebert, P.N. Marino, J.K. Oh, O.A. Smiseth, et al.
Recommendations for the evaluation of left ventricular diastolic function by echocardiography.
J Am Soc Echocardiogr., 22 (2009), pp. 107-133
[11.]
V.D. Steen, G. Graham, C. Conte, G. Owens, T.A. Medsger Jr., et al.
Isolated diffusing capacity reduction in systemic sclerosis.
Arthritis Rheum., 35 (1992), pp. 765-770
[12.]
G.E. D’Alonzo, R.J. Barst, S.M. Ayres, E.H. Bergofsky, B.H. Brundage, K.M. Detre, et al.
Survival in patients with primary pulmonary hypertension Results from a national prospective registry.
Ann Intern Med., 115 (1991), pp. 343-349
[13.]
J.R. Swiston, S.R. Johnson, J.T. Granton.
Factors that prognosticate mortality in idiopathic pulmonary hypertension: A systematic review of the literature.
Resp Med., 104 (2010), pp. 1588-1607
[14.]
R.L. Benza, D.P. Miller, M. Gomberg-Maitland, R. Frantz, A.J. Foreman, C.S. Coffey, et al.
Predicting survival in pulmonary arterial hypertension.
Circulation., 122 (2010), pp. 164-172
[15.]
M. Humbert, O. Sitbon, A. Yaici, D. Montani, D. O’Callaghan, X. Jaïs, et al.
Survival in incident prevalent cohort of patients with pulmonary arterial hipertensión.
Eur Respir J., 36 (2010), pp. 549-555
[16.]
A. Campo, S. Methai, J. Le Pavec, A.L. Zaiman, L.K. Hummers, D. Boyce, et al.
Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension.
Am J Respir Crit Care Med., 182 (2010), pp. 252-260
[17.]
R. Raymond, A.L. Hinderliter, P.W. Willis, D. Ralph, E.J. Caldwell, W. Williams, et al.
Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension.
J Am Coll Cardiol., 39 (2002), pp. 1214-1219
[18.]
P.R. Forfia, M.R. Fisher, S.C. Mathai, T. Housten-Harris, A.R. Hemnes, B.A. Borlaug, et al.
Tricuspid annular displacement predicts survival in pulmonary hypertension.
Am J Respir Crit Care Med., 174 (2006), pp. 1034-1041
[19.]
C. Tei, K.S. Dujardin, D.O. Hodge, K.R. Bailey, M.D. McGoon, A.J. Tajik, et al.
Doppler echocardiographic index for assessment of global right ventricular function.
J Am Soc Echocardiogr., 9 (1996), pp. 838-847
[20.]
S. Miyamoto, N. Nagaya, T. Satoh, S. Kyotani, F. Sakamaki, M. Fujita, et al.
Clinical correlates and prognostic significance of six minute walk test in patients with primary pulmonary hypertension: comparision with cardiopulmonary exercise testing.
Am J Respir Crit Care Med., 161 (2000), pp. 487-492
[21.]
G. Paciocco, F. Martinez, E. Bossone, E. Pielsticker, E. Gillispie, M. Rubenfire, et al.
Oxygen desaturation on the six minute walk test mortality in untreated primary pulmonary hypertension.
Eur Respir J., 17 (2001), pp. 647-652
[22.]
R. Wenser, C.F. Opitz, S.D. Anker, J. Winkler, G. Hoffken, F.X. Kleber, et al.
Assessment of survival in patients with primary pulmonary hypertension Importance of cardiopulmonary exercise testing.
Circulation., 106 (2002), pp. 319-324
[23.]
A. Fijalkowska, M. Kurzyna, A. Torbicki, G. Szewczyk, M. Florczyk, P. Pruszczyk, et al.
Serum N terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension.
Chest., 129 (2006), pp. 1313-1321
Copyright © 2011. Sociedad Española de Neumología y Cirugía Torácica
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?